glp-1 compounding crackdown news october 2025 September 15, 2025: Telehealth company must stop implying its compounded GLP -1 is FDA-approved, warns FDA – Partnership for Safe Medicines FDA Warns on Certain Forms

However, as these drugs continue to rise in popularity and demand, we are still in the early stages of fully understanding what the primary applications may be for off-label use

Our medical team closely monitors all patients on GLP-1 medications to ensure safety, manage any potential side effects, and maximize positive outcomes

Rebound was most pronounced post-discontinuation, with semaglutide 2.4 mg showing an MD of approximately -5.15 kg and exenatide approximately -3.06 kg, reflecting substantial regression toward baseline weights within a few months after therapy cessation

They also give families a chance to hold manufacturers accountable and get some measure of justice for the loss

Caan BJ, Cespedes Feliciano EM, Prado CM, et al